A Silver Lining for British Biotech and ImmunoGen
British Biotech acquired EU and Japanese rights to ImmunoGen's preclinical cancer compound, huN901-DM1. As part of the deal, British Biotech also will be responsible, on a contract basis, for US clinical development of the drug. ImmunoGen retains US product rights, allowing it to establish the drug's value before out-licensing. For British Biotech, which has reorganized, the deal is typical of its new strategy of emphasizing its development capabilities, acting in a CRO-like manner for other companies. ImmunoGen is also enjoying something of a renaissance, having inked two deals with Genentech, which will apply ImmunoGen technology to develop monoclonal antibody/drug conjugates.
You may also be interested in...
A bunch of UK biotech firms are in trouble, some forced to restructure and others to seek financing on miserably expensive terms. All wish they'd raised more money during the funding bonanza of 2000. Challenging times such as these reveal lingering cracks--and lack of experience--in strategy and business management. This suggests that UK industry, although it has matured significantly since the brutal blow to confidence dealt by a major product failure at British Biotech during the sector's tender early years, still has some way to go.
FDA concluded that original formulation of brain hemorrhage treatment was not discontinued for safety or effectiveness reasons, saying Arbor had other options to reduce risk of confusion between the new and original formulations. But the sponsor argues that withdrawal was part of FDA-approved risk mitigation plan.
Despite AI and digital analytics playing an increasing role in pharma, the industry lags others globally, a recent event heard. Meanwhile, top Indian players including Sun Pharma, Cipla and others shared what is driving their initiatives, ranging from a 'touchless factory' to virtual training and lessons learned along the way.